Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: Considerations in the elderly

Drugs and Aging

Volumn 28, Issue 3, 2011, Pages 163-176

  Goede, Valentin ^a   Hallek, Michael ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Afutuzumab, therapeutic use; Bendamustine, therapeutic use; Chlorambucil, therapeutic use; Chronic lymphocytic leukaemia, treatment; Cyclophosphamide, therapeutic use; Elderly; Fludarabine, therapeutic use; Lenalidomide, therapeutic use; Ofatumumab, therapeutic use; Research and development; Rituximab, therapeutic use

Indexed keywords

4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DASATINIB; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; LUMILIXIMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OBINUTUZUMAB; OBLIMERSEN; OFATUMUMAB; PENTOSTATIN; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE;

ALOPECIA; ANEMIA; AUTOIMMUNE HEMOLYTIC ANEMIA; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DERMATITIS; DIARRHEA; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; EDEMA; FEBRILE NEUTROPENIA; GERIATRIC DISORDER; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION; LEUKEMIA RELAPSE; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROGRESSIVE MULTIFOCAL LEUKENCEPHALOPATHY; RASH; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

AGED; ANTINEOPLASTIC AGENTS; FRAIL ELDERLY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHYSICAL FITNESS; STEM CELLS;

EID: 79951893501     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11587650-000000000-00000     Document Type: Review

References (81)

1. Foon KA, Hallek MJ. Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia 2010 Mar; 24 (3): 500-11
2. Lin TS. New agents in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2010 Jan; 5 (1): 29-34
3. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996 May 25; 347 (9013): 1432-8 (Pubitemid 26161205)
4. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001 Oct 15; 98 (8): 2319-25
5. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000 Dec 14; 343 (24): 1750-7
6. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in firstline therapy of younger patients with chronic lymphocytic leukemia. Blood 2006 Feb 1; 107 (3): 885-91 (Pubitemid 43156283)
7. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007 Jul 21; 370 (9583): 230-9 (Pubitemid 47069536)
8. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007 Mar 1; 25 (7): 793-8 (Pubitemid 350002879)
9. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009 Sep 10; 27 (26): 4378-84
10. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007 Dec 10; 25 (35): 5616-23
11. Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group [abstract no. 535]. Blood 2009; 114 (22)
12. Altekruse SF, Kosary CL, Krpacho M, et al. SEER stat fact sheets: chronic lymphocytic leukemia. SEER cancer statistics review, 1975-2007. Bethesda (MD): National Cancer Institute [online]. Available from URL: http://seer.cancer.gov/ statfacts/html/clyl.html [Accessed 2010 Aug 1]
13. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009 Oct 15; 114 (16): 3382-91
14. Hillmen P, Gribben JG, Follows GA, et al. An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL) [abstract no. 3428]. Blood 2009; 114 (22)
15. Ferrajoli A, O'Brien S, Wierda W, et al. Lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia (CLL) [abstract no. 45]. Blood 2008; 112 (11)
16. Ferrajoli A, O'Brien S, Wierda W, et al. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients [abstract no. 87]. Leuk Lymphoma 2005; 46 (Suppl. 1)
17. Forconi F, Fabbri A, Lenoci M, et al. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic leukaemia. Hematol Oncol 2008 Dec; 26 (4): 247-51
18. Bezares RF, Murro HH, Celebrin L, et al. Fludarabine (F) administered on a three (F3a) alternate day-basis in selected CLL patients [abstract no. 53]. Leuk Lymphoma 2001; 42 (Suppl. 1)
19. Marotta G, Bigazzi C, Lenoci M, et al. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica 2000 Dec; 85 (12): 1268-70 (Pubitemid 32063696)
20. Shvidel L, Shtalrid M, Bairey O, et al. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma 2003 Nov; 44 (11): 1947-50 (Pubitemid 37369629)
21. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 Jun 15; 111 (12): 5446-56
22. Shanafelt TD, Rabe KG, Kay NE, et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer 2010 Oct 15; 116 (20): 4777-87
23. Gowda A, Byrd JC. Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia. Curr Opin Hematol 2006 Jul; 13 (4): 266-72 (Pubitemid 44288904)
24. Josefsson P, Geisler CH, Leffers H, et al. CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood 2007 Jun 1; 109 (11): 4973-9 (Pubitemid 46827796)
25. Cramer P, Goede V, Jenke P, et al. Impact of different chemotherapy regimen in comorbid patients with advanced chronic lymphocytic leukemia: metaanalysis of two phase-III-trials of the German CLL Study Group [abstract no. 2840]. Blood 2006; 108 (11)
26. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine in the treatment of chronic lymphocytic leukemia: consistent superiority over chlorambucil in elderly patients and across clinically defined risk groups [abstract no. 2367]. Blood 2009; 114 (22)
27. Hallek M, Fingerle-Rowson G, Fink A-M, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression- free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL) [abstract no. 325]. Blood 2008; 112 (11)
28. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007 Jan 15; 109 (2): 405-11 (Pubitemid 46105933)
29. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009 Mar 20; 27 (9): 1492-501
30. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005 Oct; 90 (10): 1357-64 (Pubitemid 41503651)
31. Koppler H, Heymanns J, Pandorf A, et al. Bendamustine plus mitoxantrone: a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study. Leuk Lymphoma 2004 May; 45 (5): 911-3 (Pubitemid 38444666)
32. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008 Jan; 49 (1): 49-56 (Pubitemid 351146882)
33. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989 Jul; 74 (1): 19-25 (Pubitemid 19187405)
34. Juliusson G, Christiansen I, Hansen MM, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996 Jul; 14 (7): 2160-6 (Pubitemid 26230120)
35. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. J Clin Oncol 1989 Apr; 7 (4): 433-8 (Pubitemid 19098136)
36. Robertson LE, O'Brien S, Kantarjian H, et al. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 1995 Sep; 9 (9): 1444-9
37. German CLL Study Group. Fludarabine and darbepoetin alfa in treating older patients with chronic lymphocytic leukemia [ClinicalTrials.gov Identifier NCT00281892]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]
38. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001 Apr 15; 19 (8): 2165-70 (Pubitemid 32366970)
39. Castro JE, James DF, Sandoval-Sus JD, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009 Oct; 23 (10): 1779-89
40. Tam CS, O'Brien S, Wierda W, et al. Long term results of the fludarabine, cyclophosphamide and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008 Aug 15; 112 (4): 975-80
41. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010 Apr 1; 28 (10): 1756-65
42. Lamanna N, Weiss MA. Pentostatin, cyclophosphamide, and rituximab show significant clinical activity in patients with previously untreated chronic lymphocytic leukemia. Curr Oncol Rep 2007 Sep; 9 (5): 335-6
43. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006 Apr 1; 24 (10): 1575-81 (Pubitemid 46638781)
44. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG) [abstract no. 205]. Blood 2009; 114 (22)
45. Fischer K, Stilgenbauer S, Schweighofer C, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG) [abstract no. 320]. Blood 2008; 112 (11)
46. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009 Feb 1; 27 (4): 498-503
47. Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 2010 Jun; 51 (6): 983-94
48. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010 Apr 1; 28 (10): 1749-55
49. Morschhauser F, Cartron G, Lamy T, et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia [abstract no. 884]. Blood 2009; 114 (22)
50. Hoffmann-La Roche. CLL11: a study of RO5072759 with chlorambucil in patients with previously untreated chronic lymphocytic leukemia [ClinicalTrials.gov Identifier NCT01010061]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]
51. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002 May 15; 99 (10): 3554-61 (Pubitemid 34534522)
52. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005 Oct 1; 23 (28): 7024-31
53. Engert A, Gercheva L, Robak T, et al. Improved progression- free survival (PFS) of alemtuzumab (Campath®, MabCampath®) plus fludarabine (Fludara®) versus fludarabine alone as second-line treatment of patients with B-cell chronic lymphocytic leukemia: preliminary results from a phase III randomized trial [abstract no. 537]. Blood 2009; 114 (22)
54. Wierda WG, Obrien S, Ferrajoli A, et al. Salvage therapy with combined cyclophosphamide (C), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLL [abstract no. 719]. Blood 2005; 106 (11)
55. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002 Aug 8; 347 (6): 452-3 (Pubitemid 34851846)
56. Cortelezzi A, Pasquini MC, Gardellini A, et al. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 2009 Nov; 23 (11): 2027-33
57. Elter T, James R, Stilgenbauer S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide and alemtuzumab (FC-Cam) in patients with relapsed or genetic high-risk CLL: final analysis of the CLL2L trial of the German CLL Study Group [abstract no. 209]. Blood 2009; 114 (22)
58. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008 Jun 1; 111 (11): 5291-7
59. Ferrajoli A, Badoux XC, O'Brien S, et al. Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) [abstract no. 206]. Blood 2009; 114 (22)
60. Lin TS. Lenalidomide: what is the right dose in CLL? [letter]. Blood 2008 Jun 1; 111 (11): 5268
61. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007 Jan; 21 (1): 12-7 (Pubitemid 44921829)
62. Caballero D, Garcia-Marco JA,Martino R, et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 2005 Nov 1; 11 (21): 7757-63 (Pubitemid 41611619)
63. Moreno C, Villamor N, Colomer D, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005 May 20; 23 (15): 3433-8
64. Pavletic SZ, Khouri IF, Haagenson M, et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant Research. J Clin Oncol 2005 Aug 20; 23 (24): 5788-94
65. Pavletic ZS, Arrowsmith ER, Bierman PJ, et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant 2000 Apr; 25 (7): 717-22 (Pubitemid 30189511)
66. Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2009: 602-9
67. Toze CL, Sangara RN, Connors JM, et al. Impact of comorbidity index on outcome with allogeneic hematopoetic stem cell transplantation for chronic lymphocytic leukemia [abstract no. 3305]. Blood 2008; 112 (11)
68. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000; 5 (3): 224-37 (Pubitemid 30429942)
69. Reynolds C, Di Bella N, Lyons RM, et al. Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia [abstract no. 327]. Blood 2008; 112 (11)
70. Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009 Jul 1; 115 (13): 2824-36
71. Montserrat E, Moreno C, Esteve J, et al. How I treat refractory CLL. Blood 2006 Feb 15; 107 (4): 1276-83 (Pubitemid 43242359)
72. Zenz T, Mohr J, Edelmann J, et al. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma 2009 Mar; 50 (3): 510-3
73. GlaxoSmithKline. Ofatumumab + chlorambucil vs. chlorambucil monotherapy in previously untreated patients with chronic lymphocytic leukemia (COMPLEMENT 1) [ClinicalTrials.gov Identifier NCT00748189]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2010 Nov 29]
74. Celgene Corporation. Study of the effectiveness & safety of lenalidomide versus chlorambucil as first line therapy for elderly patients with B-cell CLL (the ORIGIN trial) [ClinicalTrials.gov Identifier NCT00910910]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]
75. Centre Hospitalier Universitaire Bretonneau de Tours. Fludarabine, cyclophosphamide, and rituximab followed by rituximab or observation in treating older patients with previously untreated B-cell chronic lymphocytic leukemia [ClinicalTrials.gov Identifier NCT00645606]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jan 10]
76. Hoffmann-La Roche. A study of MabThera added to bendamustine or chlorambucil in patients with chronic lymphocytic leukemia (MaBLe) [ClinicalTrials.gov Identifier NCT01056510]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2010 Nov 29]
77. Hoffmann-La Roche. A study of MabThera (rituximab) plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia [ClinicalTrials.gov Identifier NCT00738374]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2010 Nov 29]
78. Chronic Lymphocytic Leukemia Research Consortium. Multi-center trial of Revlimid® and rituximab, for first-line treatment of chronic lymphocytic leukemia (CLL) [ClinicalTrials. gov Identifier NCT00628238]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]
79. University of Kentucky. Frontline treatment with bendamustine in combination with rituximab in adults age 65 or older with chronic lymphocytic leukemia (CLL) [Clinical- Trials.gov Identifier NCT00758693]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]
80. Sarah Cannon Research Institute. Ofatumumab for patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma [ClinicalTrials.gov Identifier NCT01113632]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2010 Nov 29]
81. Memorial Sloan-Kettering Cancer Center. Lenalidomide in patients with chronic lymphocytic leukemia older than 65 years of age [ClinicalTrials.gov Identifier NCT01011894]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 29]